华北制药
(600812)
| 流通市值：100.88亿 | | | 总市值：100.88亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,484,828,636.64 | 5,275,037,790.2 | 2,574,254,051.92 | 9,869,575,819.11 |
| 营业收入 | 7,484,828,636.64 | 5,275,037,790.2 | 2,574,254,051.92 | 9,869,575,819.11 |
| 二、营业总成本 | 7,258,017,573.93 | 5,064,452,841.41 | 2,469,225,602.07 | 9,602,162,210.85 |
| 营业成本 | 5,295,459,714.07 | 3,712,471,185.76 | 1,816,338,278.92 | 6,714,658,593.44 |
| 税金及附加 | 81,610,453.98 | 58,901,920.86 | 26,799,221.61 | 109,275,550.51 |
| 销售费用 | 969,584,616.21 | 682,307,914.65 | 321,958,401.87 | 1,433,292,527.42 |
| 管理费用 | 395,365,377.85 | 264,978,738.01 | 134,047,050.91 | 581,885,940.9 |
| 研发费用 | 253,811,956.49 | 169,073,874.09 | 80,967,533.71 | 337,275,440.94 |
| 财务费用 | 262,185,455.33 | 176,719,208.04 | 89,115,115.05 | 425,774,157.64 |
| 其中:利息费用 | 276,486,185.63 | 190,640,852.41 | 97,396,371.32 | 458,698,019.11 |
| 其中:利息收入 | 16,631,110.47 | 13,034,013.73 | 6,554,100.01 | 25,255,785.32 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 42,102,545.14 | 26,285,765.54 | 7,596,720.83 | 46,164,658.18 |
| 资产处置收益 | 759,717.4 | -9,846.67 | 4,253.94 | 444,156.56 |
| 资产减值损失(新) | 28,637,601.76 | 7,432,452.04 | 6,614,126.09 | -16,374,073.77 |
| 信用减值损失(新) | -34,909,777.16 | -38,886,024.62 | -21,594,563.99 | -22,675,856 |
| 其他收益 | 23,503,062.51 | 8,366,394.1 | 5,266,449.31 | 36,708,667.71 |
| 四、营业利润 | 286,904,212.36 | 213,773,689.18 | 102,915,436.03 | 311,681,160.94 |
| 加:营业外收入 | 1,067,182.69 | 633,098.54 | 375,653.51 | 6,936,839.19 |
| 减:营业外支出 | 755,839.43 | 370,543.27 | 138,827.07 | 8,785,487.37 |
| 五、利润总额 | 287,215,555.62 | 214,036,244.45 | 103,152,262.47 | 309,832,512.76 |
| 减:所得税费用 | 75,676,686.45 | 51,749,387.85 | 26,526,600.48 | 94,865,994.43 |
| 六、净利润 | 211,538,869.17 | 162,286,856.6 | 76,625,661.99 | 214,966,518.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 211,538,869.17 | 162,286,856.6 | 76,625,661.99 | 214,966,518.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 158,504,018.75 | 123,497,402.89 | 57,491,586.04 | 126,992,370.2 |
| 少数股东损益 | 53,034,850.42 | 38,789,453.71 | 19,134,075.95 | 87,974,148.13 |
| 扣除非经常损益后的净利润 | 143,324,253 | 119,946,433.69 | 55,215,276.48 | 112,879,831.22 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.07 | 0.03 | 0.07 |
| (二)稀释每股收益 | 0.09 | 0.07 | 0.03 | 0.07 |
| 八、其他综合收益 | -209,831.87 | -412,469.02 | 39,722.88 | 1,601,601.48 |
| 归属于母公司股东的其他综合收益 | -209,831.87 | -412,469.02 | 39,722.88 | 1,601,601.48 |
| 九、综合收益总额 | 211,329,037.3 | 161,874,387.58 | 76,665,384.87 | 216,568,119.81 |
| 归属于母公司股东的综合收益总额 | 158,294,186.88 | 123,084,933.87 | 57,531,308.92 | 128,593,971.68 |
| 归属于少数股东的综合收益总额 | 53,034,850.42 | 38,789,453.71 | 19,134,075.95 | 87,974,148.13 |
| 公告日期 | 2025-10-25 | 2025-08-14 | 2025-04-24 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |